Benazepril hydrochloride veterinary-grade active pharmaceutical ingredient is supplied for direct formulation into tablets, injections, capsules, powders, granules, premixes, and solutions. The product is identified chemically as the hydrochloride salt of CAS 86541-75-5, with the molecular formula C₂₄H₂₈N₂O₅·HCl and molecular weight 460.95 g/mol. The model designation on release documents is the anhydrous hydrochloride salt of (3S)-3-[(1S)-1-ethoxycarbonyl-3-phenylpropyl]amino-2,3,4,5-tetrahydro-1H-1-benzazepin-2-one, supplied as a white to almost-white crystalline powder. The API is not a formulated product; it contains no diluents, binders, flavorings, or preservatives. The same active species is used across the listed dosage forms, while the material is graded by particle size, residual solvent profile, bioburden, and endotoxin level according to the intended route of administration. As a prodrug, benazepril requires in vivo esterase-catalyzed conversion to benazeprilat, but the physical release specification of the veterinary-grade API is fixed independently of that metabolic step.

The API is stored in tightly closed double polyethylene liners with a desiccant sachet, at 15–25°C and protected from light and moisture. Long-term stability under 25°C and 60% RH supports a retest interval of 24 months; the absence of a hydrate form is confirmed by X-ray powder diffraction because the anhydrous salt is preferred for non-aqueous granulation and dry direct compression. The powder should be handled under local extraction. No unusual hygroscopicity is observed below 60% RH, but prolonged exposure above 75% RH can increase water content and should be avoided before dry-compression weighing.

Polymorphic form is controlled by X-ray powder diffraction and differential scanning calorimetry. Differential scanning calorimetry shows a single endothermic event at 188–190°C for the intact hydrochloride anhydrous form; any additional melt before 185°C triggers polymorph identity review. The XRPD pattern is compared with the reference standard pattern stored in the regulatory dossier. These controls are important for tablets prepared by dry granulation because crystal habit changes can alter compactibility and ejection force. If jet milling generates amorphous content above 5%, a re-conditioning step at 25°C/60% RH for 24 h is applied before final blending.

What Are the Pharmacopeial Purity Limits and Physical Release Criteria for This Multi-Route API?

The product is released against a specification derived from USP and Ph.Eur. benazepril hydrochloride monographs, with additional particle-size and microbiological controls for veterinary premix and parenteral applications. Identification is established by infrared absorption compared with a reference standard, by HPLC retention time, and by chloride reaction of the salt. The assay is determined by HPLC using USP <621>; the acceptance range is 98.0–102.0% on the anhydrous basis. Impurity control is based on area normalization: benazeprilat, the hydrolysate and pharmacologically active metabolite, is limited to not more than 0.5%; any unspecified impurity is limited to 0.10%; and total impurities are limited to 1.0%. Water by Karl Fischer titration is controlled below 0.5%, and residue on ignition is not more than 0.1%.

The HPLC method uses a 150 × 4.6 mm octadecylsilane column with 5 µm particles, column temperature 30°C, and UV detection at 240 nm; the mobile phase is a phosphate buffer–acetonitrile gradient. System suitability requires resolution of benazepril and benazeprilat not less than 2.0, tailing factor not more than 2.0, and relative standard deviation for replicate injections not more than 1.0%.

The residual solvent profile is set by the final crystallization and drying operations. If methanol is retained, the class 2 limit of 3000 ppm applies; ethyl acetate and isopropanol, where used, are class 3 solvents with the standard limit of 5000 ppm. For parenteral grades, a more conservative control of 600 ppm for the sum of quantifiable organic volatiles is often applied because the API enters an aqueous injectable solution without further solvent-removal capability. Elemental impurities are measured by ICP-MS after closed-vessel microwave digestion, and the limits are assigned from ICH Q3D Option 1; for veterinary oral and premix formulations, the oral permitted daily exposures are used, while parenteral products are assessed against the parenteral PDE levels. Nitrosamine risk is evaluated under ICH M7 and the current regional veterinary nitrosamine guidance; the release certificate reports results for N-nitrosodimethylamine and N-nitrosodiethylamine when the jurisdiction requests them.

Particle size is determined by laser diffraction on a dry dispersion module at 1.5 bar pressure and obscuration 0.5–6.0%, following ISO 13320:2020. The D50 and D90 values are calculated using the Mie theory with a refractive index of 1.53 and absorption 0.1. The method is used because the powder may be cohesive after milling; dry dispersion with compressed air reduces agglomerates, but the air pressure must not exceed 3.0 bar to avoid particle fracture.

Binary compatibility screening by differential scanning calorimetry and HPLC at 40°C/75% RH for 28 days indicates that the hydrochloride salt is compatible with microcrystalline cellulose, lactose monohydrate, crospovidone, and magnesium stearate. Alkaline buffers and strong oxidizing agents should be avoided in the same powder because base-catalyzed ester cleavage can generate benazeprilat and reduce assay. For liquid formulations, sodium metabisulfite is not recommended as an antioxidant due to pH interaction; nitrogen sparging of the filling vessel is used instead.

Oral solid-dosage manufacture places the greatest demand on particle-size distribution, bulk density, and dry-binder compatibility. In direct-compression blends, the API is first pre-dispersed in a turbo-charged bin blender at 6–10 rpm for 10–15 min with a portion of microcrystalline cellulose; the remaining diluent and disintegrant are added, followed by magnesium stearate at 0.5–1.0% w/w with a final lubrication step of 3 min. Batch-to-batch variability in content uniformity is reduced when the API fraction is kept below 5% of the total tablet mass and the D90 of the API is below 250 µm. If the API is added directly without a pre-mix, segregation at the hopper wall and punch-die fill variation have been observed on rotary tablet presses operating above 40,000 tablets/h; the preferred corrective action is geometric dilution of the API with the dry binder prior to the main blending stage.

Wet-granulation routes are used when the direct-compression blend lacks sufficient flow. The API is dispersed in a high-shear granulator with a hydrophilic binder solution; after granulation, drying in a fluid-bed dryer is controlled to a product temperature not exceeding 40°C and a final loss on drying of 1.0–2.0% w/w. Over-dried granules below 1.0% moisture have shown increased friability and capping during compression, while granule moisture above 3.0% can reduce dissolution and promote sticking. The milled API grade for wet granulation does not require pre-micronization, but the D50 must remain above 10 µm to avoid dusting and operator exposure. Capsule filling uses a dosator or dosing-disc machine; the API is pre-blended to an assay relative standard deviation below 3.0% across 10 sampling points before encapsulation.

For low-dose premixes, oral powders, and granules, the API is co-milled or geometric-diluted with lactose monohydrate or calcium carbonate to achieve a working concentration of 0.5–5.0%. Homogeneity is assessed at the beginning, middle, and end of the blender discharge. Production-scale experience with low-dose premixes shows that assay RSD increases when the carrier is added before the API is fully dispersed; a preferred sequence is to triturate the API with an equal mass of carrier, pass the triturate through a 600 µm screen, then load it into a ribbon blender. Failure to pass the triturate through a screen can leave visible API aggregates and raise RSD above 8% at the first sampling port. A ribbon blender with intensifier bar operating for 8–12 min typically reduces assay RSD below 5.0% when the API D90 is ≤ 75 µm. Premixes containing benazepril hydrochloride at 1% activity are packed in multiwall paper sacks with a moisture barrier layer. A stability-indicating HPLC method is used to monitor benazeprilat formation and assay loss in the premix; the premix shelf-life is assigned by stability data, typically 6–12 months at 25°C/60% RH, because the high surface area of the carrier can increase water exposure. Dry storage is required; premix granulation with liquid water or steam should be avoided.

When the API Is Processed into Sterile Injections, Solutions, or Carrier-Based Premixes, Which Boundaries Apply?

Parenteral-grade benazepril hydrochloride requires a low-endotoxin, low-bioburden powder and a solubility strategy appropriate for the intended final pH. Benazepril hydrochloride solubility in water is pH-dependent and generally lower than that of enalapril maleate. In unbuffered water, saturation is below the concentration needed for a single-dose injectable solution at room temperature; therefore the compounding pharmacy uses an acid-buffer or cosolvent system. The API is dissolved in the compounding suite with a buffer system; the solution is then passed through a 0.45 µm prefilter and a sterilizing-grade membrane filter at 0.22 µm. The filling line is operated under Grade A laminar airflow with Grade B background, and the sterilized solution is filled into depyrogenated glass vials or overwrapped flexible bags. Filter integrity testing is performed before and after filling by bubble-point or diffusive-flow method.

For this route, the API is tested for bacterial endotoxins under USP <85>; a representative acceptance limit is ≤ 0.5 EU/mg, calculated from the maximum intended dose and the water-for-injection volume, but lower limits are applied when the product is labelled for small patients or when the final dose exceeds 1 mg/kg. The sterile API is packaged in double polyethylene liners and released with a bioburden of not more than 10 CFU/g. Precipitation at cold storage has been observed if the pH rises above the formulation range or if the solution is diluted with normal saline; compatibility with intravenous fluids must be validated at the final concentration and temperature.

Solutions for oral use are less restrictive in sterility, but chemical stability is the limiting factor. Benazepril hydrochloride is dissolved in a buffered aqueous system; the pH is fixed by stability data and is not adjusted solely by solubility. The API for this route is produced with the same impurity and residual solvent controls as the tablet grade, but the particle size may be finer because the liquid formulation is filtered through a 10 µm or 20 µm clarification filter. Microbiological challenge data are generated for the preservative system according to USP <51>; the API itself does not contain a preservative.

The veterinary grade is not a lower-purity product. The release criteria for assay, impurities, and residual solvents are the same as those used for human monograph release because the active molecule is identical. The difference lies in the documentation package and the additional feed-premix or parenteral controls: veterinary premix specifications include carrier-compatible particle size and blending homogeneity; parenteral specifications include endotoxin; a human oral monograph does not include premix RSD tests. Veterinary API manufacture is conducted under ICH Q7 with a site master file, equipment cleaning validation, and batch records that reference the same unit operations as human API: reaction, extraction, charcoal treatment, crystallization from organic solvent, washing, vacuum drying, milling, and final blending.

Clearance Pathway and Physicochemical Identity Relative to Enalapril Maleate and Lisinopril

In the class of ACE inhibitors used in veterinary medicine, benazepril hydrochloride differs from enalapril maleate and lisinopril dihydrate in its activation state and clearance routes. Benazepril is a prodrug that must be de-esterified by hepatic esterases to benazeprilat; enalapril maleate is also a prodrug and is converted to enalaprilat, while lisinopril is administered as the active diacid and does not require metabolic activation. Benazeprilat is eliminated by both biliary and urinary routes; enalaprilat and lisinopril rely predominantly on renal clearance. This property is reproduced in the raw-material dossier, not as a formulation claim: the same API lot can be used for a dog tablet and a cat oral solution because the species-specific clearance profile is a function of the active metabolite, not of the salt or the granulated matrix.

Physicochemically, benazepril hydrochloride is less water-soluble than lisinopril dihydrate, which alters the manufacturing route. Lisinopril can be wet-granulated at high drug loading without a solubility aid, whereas benazepril hydrochloride at the same loading may require a surfactant or a dry granulation step. The veterinary-grade API therefore includes a specified particle-size fraction for direct compression and premixes, while lisinopril monohydrate specifications often focus on bulk density and crystal habit. Against enalapril maleate, benazepril hydrochloride is supplied as the hydrochloride rather than the maleate salt; the counterion difference affects the theoretical active base content, so assay in salt form is expressed on the anhydrous benazepril hydrochloride basis and is not interchangeable with enalapril maleate potencies.

The difference in clearance is reflected in target-species selection. In cats with chronic kidney disease, benazepril is selected because the biliary excretion of benazeprilat reduces dependence on glomerular filtration, but this is a clinical pharmacology attribute of the metabolite, not a difference in the API monograph. The raw material must nevertheless be free of the active metabolite benazeprilat beyond the specified limit because the metabolite should not be present in the tablet core before administration. The principal limitation of the benazepril veterinary-grade API is that it is not a direct formulation; downstream milling, blending, or sterile processing remains necessary. The material is not interchangeable on an equal-mass basis with benazepril free base, enalapril maleate, or lisinopril dihydrate, and potency adjustments must be made using the molecular weight of the chosen salt and the intended dosage form. For aqueous injectable compounding, benazepril hydrochloride is processed with buffer after pH adjustment; published stability data for extemporaneous veterinary injections are limited, and the responsible veterinarian or pharmacist must confirm compatibility with the final container and sterilization cycle.